Drugs / Acalabrutinib
Acalabrutinib
Drug FDA approvedMarketed as Calquence
Bruton's tyrosine kinase (BTK) inhibitor·First approved·2017·1 brand
- Registered trials
- 122
- Ongoing
- 79/ 65%
- Completed
- 29
- Indications
- 3
Approved indications by brand
| Brand | Indication |
|---|---|
| Calquence | Mantle cell lymphoma |
| Chronic lymphocytic leukemia | |
| Small lymphocytic lymphoma |
Clinical trial landscape
122 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 63 | 44 | 13 | |
| Phase 1/2 | 17 | 10 | 3 | |
| Phase 3 | 17 | 14 | 1 | |
| Phase 1 | 16 | 4 | 10 | |
| Unknown | 4 | 3 | 1 | |
| Not applicable | 2 | 1 | 1 | |
| Phase 2/3 | 1 | 1 | 0 | |
| Early Phase 1 | 1 | 1 | 0 | |
| Phase 4 | 1 | 1 | 0 | |
| All phases | 122 | 79 | 29 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Blocks Bruton's tyrosine kinase (BTK) to reduce survival and growth signaling in malignant B cells.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.